Početna stranicaPRE • NASDAQ
add
Prenetics Global Ltd
4,42 $
Poslije radnog vremena:(5,20 %)+0,23
4,65 $
Zatvoreno: 22. stu, 20:00:00 GMT -5 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
4,61 $
Dnevni raspon
4,42 $ - 4,42 $
Godišnji raspon
2,85 $ - 7,84 $
Tržišna kapitalizacija
54,00 mil. USD
Prosječna količina
11,72 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
GS
1,12 %
0,35 %
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
(USD) | lip 2024.info | Godišnja promjena |
---|---|---|
Prihod | 5,94 mil. | 4,32 % |
Operativni troškovi | 14,38 mil. | 0,52 % |
Neto dohodak | −10,72 mil. | 50,83 % |
Neto profitabilnost | −180,46 | 52,87 % |
Zarada po dionici | — | — |
EBITDA | −9,51 mil. | 13,59 % |
Efektivna porezna stopa | 0,79 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
(USD) | lip 2024.info | Godišnja promjena |
---|---|---|
Gotovinska i kratkoročna ulaganja | 63,89 mil. | −67,46 % |
Ukupna imovina | 233,31 mil. | −16,93 % |
Ukupne obveze | 42,30 mil. | −30,22 % |
Ukupni kapital | 191,00 mil. | — |
Dionice u optjecaju | 12,22 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,30 | — |
Povrat imovine | −11,12 % | — |
Povrat kapitala | −13,33 % | — |
Tok novca
Neto promjena novca
(USD) | lip 2024.info | Godišnja promjena |
---|---|---|
Neto dohodak | −10,72 mil. | 50,83 % |
Gotovina od poslovanja | — | — |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | — | — |
Neto promjena novca | — | — |
Slobodan tok novca | — | — |
Više
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Osnovano
2014
Web-lokacija
Zaposlenici
322